SHELTON, Conn., June 30, 2025 /PRNewswire/ -- Intensity Therapeutics, Inc. (INTS) ("Intensity" or "the Company"), a late-stage clinical biotechnology company focused on the discovery and development ...
The paper features a comprehensive evaluation of data, including disease control rate, overall survival, immune activation, abscopal effects, tumor necrosis, dose ranging, and safety The manuscript is ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback